Indian Dermatology Online Journal

REVIEW ARTICLE
Year
: 2019  |  Volume : 10  |  Issue : 5  |  Page : 503--518

Oral tofacitinib: Contemporary appraisal of its role in dermatology


Sidharth Sonthalia1, Parul Aggarwal2 
1 Medical Director and Senior Consultant Dermatologist, Department of Dermatology and Dermatosurgery, Skinnocence: The Skin Clinic and Research Center, Gurugram, Haryana, India
2 Consultant Dermatologist, Department of Dermatology and STD, Skinalive Clinic, New Delhi, India

Correspondence Address:
Parul Aggarwal
1775, Sector 10/A, Gurugram - 122 001, Haryana
India

Tofacitinib, an oral Janus kinase inhibitor (Jakinib), is an emerging treatment modality whose well-established efficacy in systemic inflammatory diseases is now being actively explored for cutaneous disorders (arising due to the patient's dysimmune responses) that are not responding to and/or sustaining intolerable adverse effects with the classical immunosuppressives and other targeted therapies such as the biologics. The most common dermatoses for which oral as well as topical Jakinibs such as tofacitinib have been evaluated and are being used albeit as an off-label indication include psoriasis, psoriatic arthritis, alopecia areata, vitiligo, and atopic dermatitis. This article provides a succinct review on the current status of oral tofacitinib in dermatology through literature search of PubMed database and stresses on the need for further evidence generation to define the drug's place in the therapeutic arsenal of dysimmune cutaneous disorders.


How to cite this article:
Sonthalia S, Aggarwal P. Oral tofacitinib: Contemporary appraisal of its role in dermatology.Indian Dermatol Online J 2019;10:503-518


How to cite this URL:
Sonthalia S, Aggarwal P. Oral tofacitinib: Contemporary appraisal of its role in dermatology. Indian Dermatol Online J [serial online] 2019 [cited 2019 Oct 18 ];10:503-518
Available from: http://www.idoj.in/article.asp?issn=2229-5178;year=2019;volume=10;issue=5;spage=503;epage=518;aulast=Sonthalia;type=0